$ATOS
ATOSSA THERAPEUTICS, INC.

2024 Q3 Form 10-Q Financial Statement

#000095017024095102 Filed on August 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.973M $3.552M $4.088M
YoY Change -0.9% -13.11% 29.29%
% of Gross Profit
Research & Development $3.412M $3.553M $3.705M
YoY Change -23.62% -4.1% 7.92%
% of Gross Profit
Depreciation & Amortization $4.000K $4.000K $3.000K
YoY Change 33.33% 50.0%
% of Gross Profit
Operating Expenses $6.385M $7.105M $7.793M
YoY Change -14.5% -8.83% 18.17%
Operating Profit -$6.385M -$7.105M -$7.793M
YoY Change -14.5% -8.83% 18.17%
Interest Expense $1.001M $1.073M $983.0K
YoY Change -21.18% 9.16% -1256.47%
% of Operating Profit
Other Income/Expense, Net -$136.0K -$17.00K -$30.00K
YoY Change 288.57% -43.33% -61.04%
Pretax Income -$7.230M -$6.049M -$9.830M
YoY Change 16.07% -38.46% 47.33%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$7.230M -$6.049M -$9.830M
YoY Change 16.07% -38.46% 47.33%
Net Earnings / Revenue
Basic Earnings Per Share -$0.06 -$0.05 -$0.08
Diluted Earnings Per Share -$0.06 -$0.05 -$0.08
COMMON SHARES
Basic Shares Outstanding 125.8M 125.8M 126.6M
Diluted Shares Outstanding 125.8M 125.7M 126.6M

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $74.77M $79.53M $99.39M
YoY Change -20.46% -19.99% -20.83%
Cash & Equivalents $74.80M $79.50M $99.39M
Short-Term Investments
Other Short-Term Assets $2.345M $2.192M $7.000K
YoY Change 33400.0% 31214.29% -99.55%
Inventory
Prepaid Expenses $950.0K $987.0K $5.759M
Receivables
Other Receivables
Total Short-Term Assets $77.11M $81.72M $106.0M
YoY Change -21.03% -22.91% -20.55%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $1.710M $1.710M
YoY Change -100.0% 0.0%
Other Assets $2.366M $2.430M $642.0K
YoY Change 1.24% 278.5% 2.39%
Total Long-Term Assets $2.366M $4.140M $2.352M
YoY Change -41.54% 76.02% 275.12%
TOTAL ASSETS
Total Short-Term Assets $77.11M $81.72M $106.0M
Total Long-Term Assets $2.366M $4.140M $2.352M
Total Assets $79.48M $85.86M $108.4M
YoY Change -21.85% -20.76% -19.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.561M $1.056M $1.174M
YoY Change 117.41% -10.05% -42.79%
Accrued Expenses $1.694M $1.907M $803.0K
YoY Change 34.34% 137.48% -3.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.796M $5.696M $3.478M
YoY Change 68.29% 63.77% -8.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.796M $5.696M $3.478M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $5.796M $5.696M $3.478M
YoY Change 68.29% 63.77% -8.28%
SHAREHOLDERS EQUITY
Retained Earnings -$205.4M -$198.2M -$172.3M
YoY Change 15.07% 15.04% 22.47%
Common Stock $22.88M $22.87M $276.8M
YoY Change -91.76% -91.73% 2.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $73.68M $80.16M $104.9M
YoY Change
Total Liabilities & Shareholders Equity $79.48M $85.86M $108.4M
YoY Change -21.85% -20.76% -19.17%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$7.230M -$6.049M -$9.830M
YoY Change 16.07% -38.46% 47.33%
Depreciation, Depletion And Amortization $4.000K $4.000K $3.000K
YoY Change 33.33% 50.0%
Cash From Operating Activities -$4.750M -$4.531M -$4.465M
YoY Change 22.42% 1.48% -24.95%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $3.000K $13.00K
YoY Change -76.92%
Acquisitions
YoY Change
Other Investing Activities -$9.000K
YoY Change
Cash From Investing Activities -$10.00K -$3.000K -$13.00K
YoY Change -76.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 100.0K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -4.750M -4.531M -4.465M
Cash From Investing Activities -10.00K -3.000K -13.00K
Cash From Financing Activities 0.000 100.0K 0.000
Net Change In Cash -4.760M -4.434M -4.478M
YoY Change -11.19% -0.98% -24.73%
FREE CASH FLOW
Cash From Operating Activities -$4.750M -$4.531M -$4.465M
Capital Expenditures $10.00K $3.000K $13.00K
Free Cash Flow -$4.760M -$4.534M -$4.478M
YoY Change 22.68% 1.25% -24.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001488039
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35610
dei Entity Registrant Name
EntityRegistrantName
ATOSSA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-4753208
dei Entity Address Address Line1
EntityAddressAddressLine1
10202 5th Avenue NE
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98125
dei City Area Code
CityAreaCode
206
dei Local Phone Number
LocalPhoneNumber
588-0256
dei Security12b Title
Security12bTitle
Common Stock, $0.18 par value
dei Trading Symbol
TradingSymbol
ATOS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
125757416
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79526000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88460000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
110000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
110000
CY2024Q2 atos Prepaid Materials
PrepaidMaterials
1095000
CY2023Q4 atos Prepaid Materials
PrepaidMaterials
1487000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
987000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2162000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
81718000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
92219000
CY2024Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
1710000
CY2023Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
1710000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2430000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2323000
CY2024Q2 us-gaap Assets
Assets
85858000
CY2023Q4 us-gaap Assets
Assets
96252000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1056000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
806000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1907000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
973000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
939000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1654000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1794000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1803000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5696000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5236000
CY2024Q2 us-gaap Liabilities
Liabilities
5696000
CY2023Q4 us-gaap Liabilities
Liabilities
5236000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1803000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5696000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5236000
CY2024Q2 us-gaap Liabilities
Liabilities
5696000
CY2023Q4 us-gaap Liabilities
Liabilities
5236000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
582
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
582
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
582
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
582
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
582
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
582
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
582
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
582
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125757416
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125757416
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125304064
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125304064
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
22874000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
22792000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
256978000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
255987000
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1320046
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1320046
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1475000
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1475000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-198215000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-186288000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
80162000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
91016000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
85858000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
96252000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3553000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3705000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7302000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7213000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3552000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4088000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6784000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7678000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
7105000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
7793000
us-gaap Operating Expenses
OperatingExpenses
14086000
us-gaap Operating Expenses
OperatingExpenses
14891000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7105000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7793000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14086000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14891000
CY2024Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125757416
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125757416
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125304064
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125304064
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
22874000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
22792000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
256978000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
255987000
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1320046
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1320046
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1475000
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1475000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-198215000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-186288000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
80162000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
91016000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
85858000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
96252000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3553000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3705000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7302000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7213000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3552000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4088000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6784000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7678000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
7105000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
7793000
us-gaap Operating Expenses
OperatingExpenses
14086000
us-gaap Operating Expenses
OperatingExpenses
14891000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7105000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7793000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14086000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14891000
CY2024Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
0
CY2023Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
2990000
us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
0
us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
2990000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1073000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
983000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2211000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1833000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-17000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-30000
CY2023Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
2990000
us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
0
us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
2990000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1073000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
983000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2211000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1833000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-17000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-30000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-52000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-63000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6049000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9830000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11927000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16111000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-6049000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9830000
us-gaap Net Income Loss
NetIncomeLoss
-11927000
us-gaap Net Income Loss
NetIncomeLoss
-16111000
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.1
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.1
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
125732140
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125732140
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
126622798
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
125525959
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125525959
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
126623450
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126623450
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
117964000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1573000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6281000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
113256000
CY2023Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
152000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1603000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9830000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
104877000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
91016000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-52000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-63000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6049000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9830000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11927000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16111000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-6049000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9830000
us-gaap Net Income Loss
NetIncomeLoss
-11927000
us-gaap Net Income Loss
NetIncomeLoss
-16111000
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.1
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
125732140
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125732140
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126622798
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
126622798
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
125525959
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125525959
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
117964000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1573000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6281000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
113256000
CY2023Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
152000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1603000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9830000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
104877000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
91016000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
204000
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
417000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-5878000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
85759000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
100000
CY2024Q2 atos Stock Issued During Period Value Stock Options Exercised1
StockIssuedDuringPeriodValueStockOptionsExercised1
228000
CY2024Q2 atos Stock Repurchased During Period For Stock Option Exercise And Taxes Value
StockRepurchasedDuringPeriodForStockOptionExerciseAndTaxesValue
-228000
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
352000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-6049000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
80162000
us-gaap Net Income Loss
NetIncomeLoss
-11927000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
204000
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
417000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-5878000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
85759000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
100000
CY2024Q2 atos Stock Issued During Period Value Stock Options Exercised1
StockIssuedDuringPeriodValueStockOptionsExercised1
228000
CY2024Q2 atos Stock Repurchased During Period For Stock Option Exercise And Taxes Value
StockRepurchasedDuringPeriodForStockOptionExerciseAndTaxesValue
-228000
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
352000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-6049000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
80162000
us-gaap Net Income Loss
NetIncomeLoss
-11927000
us-gaap Net Income Loss
NetIncomeLoss
-16111000
us-gaap Share Based Compensation
ShareBasedCompensation
769000
us-gaap Share Based Compensation
ShareBasedCompensation
3176000
us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
0
us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
2990000
us-gaap Depreciation
Depreciation
9000
us-gaap Depreciation
Depreciation
6000
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-4000
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-392000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-785000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1175000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
91000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
111000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
250000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1943000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
934000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-256000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-715000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-70000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-9000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
27000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9229000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11487000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
304000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
304000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8934000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11500000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
88570000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
111000000
us-gaap Net Income Loss
NetIncomeLoss
-16111000
us-gaap Share Based Compensation
ShareBasedCompensation
769000
us-gaap Share Based Compensation
ShareBasedCompensation
3176000
us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
0
us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
2990000
us-gaap Depreciation
Depreciation
9000
us-gaap Depreciation
Depreciation
6000
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-4000
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-392000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-785000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1175000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
91000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
250000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1943000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
934000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-256000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-715000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-70000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-9000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
27000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9229000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11487000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
304000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8934000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11500000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
88570000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
111000000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
79636000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
99500000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79526000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99390000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
79636000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
99500000
atos Unsettled Trades For Repurchase Of Common Stock
UnsettledTradesForRepurchaseOfCommonStock
0
atos Unsettled Trades For Repurchase Of Common Stock
UnsettledTradesForRepurchaseOfCommonStock
152000
us-gaap Stock Issued1
StockIssued1
228000
us-gaap Stock Issued1
StockIssued1
0
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
79636000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
99500000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79526000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99390000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
79636000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
99500000
atos Unsettled Trades For Repurchase Of Common Stock
UnsettledTradesForRepurchaseOfCommonStock
0
atos Unsettled Trades For Repurchase Of Common Stock
UnsettledTradesForRepurchaseOfCommonStock
152000
us-gaap Stock Issued1
StockIssued1
228000
us-gaap Stock Issued1
StockIssued1
0
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTE 1: NATURE OF OPERATIONS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atossa Therapeutics, Inc. (the Company) was incorporated on April 30, 2009, in the State of Delaware to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company is focused on developing proprietary innovative medicines in areas of significant unmet medical need in oncology, with a focus on breast cancer and other breast conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Net Income Loss
NetIncomeLoss
-11900000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9200000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79500000
CY2024Q2 atos Working Capital Deficit
WorkingCapitalDeficit
76000000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassification</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain reclassifications have been made to prior period financial information to conform to the current year presentation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTE 1: NATURE OF OPERATIONS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atossa Therapeutics, Inc. (the Company) was incorporated on April 30, 2009, in the State of Delaware to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company is focused on developing proprietary innovative medicines in areas of significant unmet medical need in oncology, with a focus on breast cancer and other breast conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Net Income Loss
NetIncomeLoss
-11900000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9200000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79500000
CY2024Q2 atos Working Capital Deficit
WorkingCapitalDeficit
76000000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassification</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain reclassifications have been made to prior period financial information to conform to the current year presentation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these financial statements include the valuation of the investment in non-marketable equity securities, stock-based compensation expense, and prepaid or accrued clinical trial balances at the end of any reporting period. Actual results could differ materially from the Company’s estimates.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these financial statements include the valuation of the investment in non-marketable equity securities, stock-based compensation expense, and prepaid or accrued clinical trial balances at the end of any reporting period. Actual results could differ materially from the Company’s estimates.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of deposits of cash and cash equivalents, including those deposited in money market deposit accounts. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any material losses in such accounts and believes it is not exposed to significant risk. The Company has invested its excess cash primarily in money market funds.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of deposits of cash and cash equivalents, including those deposited in money market deposit accounts. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any material losses in such accounts and believes it is not exposed to significant risk. The Company has invested its excess cash primarily in money market funds.</span></p>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
atos Valuation Of Other Investments
ValuationOfOtherInvestments
<span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Entities</span><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews agreements it enters into with third-party entities, pursuant to which the Company may have a variable interest in the entity, in order to determine if the entity is a variable interest entity (VIE). If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that entity. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct the economically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. If the Company determines it is the primary beneficiary of a VIE, it consolidates that VIE into the Company’s Condensed Consolidated Financial Statements. The Company’s determination about whether it should consolidate such VIEs is made continuously as changes to existing relationships or future transactions may result in a consolidation or deconsolidation event. The Company currently does not consolidate any VIEs.</span></p>
atos Valuation Of Other Investments
ValuationOfOtherInvestments
<span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Entities</span><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews agreements it enters into with third-party entities, pursuant to which the Company may have a variable interest in the entity, in order to determine if the entity is a variable interest entity (VIE). If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that entity. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct the economically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. If the Company determines it is the primary beneficiary of a VIE, it consolidates that VIE into the Company’s Condensed Consolidated Financial Statements. The Company’s determination about whether it should consolidate such VIEs is made continuously as changes to existing relationships or future transactions may result in a consolidation or deconsolidation event. The Company currently does not consolidate any VIEs.</span></p>
CY2023Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
3000000
us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
3000000
CY2024Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
0
us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
0
CY2024Q2 atos Prepaid Clinical Trial Deposits
PrepaidClinicalTrialDeposits
233000
CY2023Q4 atos Prepaid Clinical Trial Deposits
PrepaidClinicalTrialDeposits
805000
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
353000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
794000
CY2024Q2 atos Professional Services Current
ProfessionalServicesCurrent
226000
CY2023Q4 atos Professional Services Current
ProfessionalServicesCurrent
501000
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
175000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
62000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
987000
CY2023Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
3000000
us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
3000000
CY2024Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
0
us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
0
CY2024Q2 atos Prepaid Clinical Trial Deposits
PrepaidClinicalTrialDeposits
233000
CY2023Q4 atos Prepaid Clinical Trial Deposits
PrepaidClinicalTrialDeposits
805000
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
353000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
794000
CY2024Q2 atos Professional Services Current
ProfessionalServicesCurrent
226000
CY2023Q4 atos Professional Services Current
ProfessionalServicesCurrent
501000
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
175000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
62000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
987000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2162000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2162000
CY2024Q2 atos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
1426000
CY2023Q4 atos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
608000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
481000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
365000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1907000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
973000
CY2024Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
564000
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1134000
CY2024Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
244000
CY2023Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
236000
CY2024Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
131000
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
284000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
939000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1654000
CY2024Q2 atos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
1426000
CY2023Q4 atos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
608000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
481000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
365000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1907000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
973000
CY2024Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
564000
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1134000
CY2024Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
244000
CY2023Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
236000
CY2024Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
131000
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
284000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
939000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1654000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1800000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1800000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1800000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 atos Consummate A Business Combination Percentage Of Acquired Outstanding Shares
ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares
0.50
CY2024Q2 atos Consummate A Business Combination Percentage Of Aggregate Ordinary Voting Power
ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower
0.50
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
21210750
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
300000
atos Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 atos Consummate A Business Combination Percentage Of Acquired Outstanding Shares
ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares
0.50
CY2024Q2 atos Consummate A Business Combination Percentage Of Aggregate Ordinary Voting Power
ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower
0.50
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
21210750
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
300000
atos Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
0
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38292683
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
39507753
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38292683
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
39507753
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38633899
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37973923
us-gaap Subsidiary Or Equity Method Investee Deferred Income Tax Provision On Cumulative Gain Loss Recognized Amount
SubsidiaryOrEquityMethodInvesteeDeferredIncomeTaxProvisionOnCumulativeGainLossRecognizedAmount
0
us-gaap Subsidiary Or Equity Method Investee Deferred Income Tax Provision On Cumulative Gain Loss Recognized Amount
SubsidiaryOrEquityMethodInvesteeDeferredIncomeTaxProvisionOnCumulativeGainLossRecognizedAmount
0
CY2024Q2 us-gaap Subsidiary Or Equity Method Investee Deferred Income Tax Provision On Cumulative Gain Loss Recognized Amount
SubsidiaryOrEquityMethodInvesteeDeferredIncomeTaxProvisionOnCumulativeGainLossRecognizedAmount
0
CY2023Q2 us-gaap Subsidiary Or Equity Method Investee Deferred Income Tax Provision On Cumulative Gain Loss Recognized Amount
SubsidiaryOrEquityMethodInvesteeDeferredIncomeTaxProvisionOnCumulativeGainLossRecognizedAmount
0
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
352000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1603000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
769000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3176000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
17506345
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.79
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
554525
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4208334
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
696504
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.04
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38633899
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37973923
us-gaap Subsidiary Or Equity Method Investee Deferred Income Tax Provision On Cumulative Gain Loss Recognized Amount
SubsidiaryOrEquityMethodInvesteeDeferredIncomeTaxProvisionOnCumulativeGainLossRecognizedAmount
0
us-gaap Subsidiary Or Equity Method Investee Deferred Income Tax Provision On Cumulative Gain Loss Recognized Amount
SubsidiaryOrEquityMethodInvesteeDeferredIncomeTaxProvisionOnCumulativeGainLossRecognizedAmount
0
CY2024Q2 us-gaap Subsidiary Or Equity Method Investee Deferred Income Tax Provision On Cumulative Gain Loss Recognized Amount
SubsidiaryOrEquityMethodInvesteeDeferredIncomeTaxProvisionOnCumulativeGainLossRecognizedAmount
0
CY2023Q2 us-gaap Subsidiary Or Equity Method Investee Deferred Income Tax Provision On Cumulative Gain Loss Recognized Amount
SubsidiaryOrEquityMethodInvesteeDeferredIncomeTaxProvisionOnCumulativeGainLossRecognizedAmount
0
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
352000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1603000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
769000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3176000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
17506345
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.79
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
554525
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4208334
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
696504
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.04
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
268998
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.85
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
4328
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
255.47
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
268998
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.85
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
4328
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
255.47
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
20744849
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.59
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M8D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2389459
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
15230527
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.8
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y7M13D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1246913
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
20744849
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.59
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y5M8D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
2389459
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.06
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.06
CY2024Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
37000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
114000
CY2023Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
50000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
106000
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
20744849
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.59
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M8D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2389459
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
15230527
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.8
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y7M13D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1246913
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
20744849
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.59
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
2389459
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.06
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.06
CY2024Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
37000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
114000
CY2023Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
50000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
106000
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-095102-index-headers.html Edgar Link pending
0000950170-24-095102-index.html Edgar Link pending
0000950170-24-095102.txt Edgar Link pending
0000950170-24-095102-xbrl.zip Edgar Link pending
atos-20240630.htm Edgar Link pending
atos-20240630.xsd Edgar Link pending
atos-ex10_2.htm Edgar Link pending
atos-ex31_1.htm Edgar Link pending
atos-ex31_2.htm Edgar Link pending
atos-ex32_1.htm Edgar Link pending
atos-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img96392089_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
atos-20240630_htm.xml Edgar Link completed